Researchers have developed an experimental nanotherapy aimed at overcoming two major challenges in treating glioblastoma: the blood-brain barrier and drug resistance. The approach uses tiny lipid particles called liposomes to carry two existing drugs—everolimus (or rapamycin) and vinorelbine—directly to tumor cells.
By delivering both drugs together, the therapy blocks tumor growth pathways and prevents cancer cells from repairing DNA damage. It also makes tumors more sensitive to radiation therapy. In preclinical studies using patient-derived tumor models, combining this nanotherapy with radiation more than doubled survival compared to untreated cases. Because the drugs are targeted, lower doses can be used, which may reduce side effects.
Glioblastoma remains one of the deadliest cancers, with average survival around 15 months. Researchers are now conducting safety and dosing studies before moving into human trials. If successful, the treatment could be given orally or intravenously alongside standard care or used for resistant tumors, though more research is needed to confirm benefits in patients.